{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:14:48Z","timestamp":1792638888993,"version":"4.5.0"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Most patients with pathogenic or likely pathogenic (P\/LP) variants for breast cancer have not undergone genetic testing.<\/jats:p><\/jats:sec>Objective<\/jats:title>To identify patients meeting family history criteria for genetic testing in the electronic health record (EHR).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This study included both cross-sectional (observation date, February 1, 2024) and retrospective cohort (observation period, January 1, 2018, to February 1, 2024) analyses. Participants included patients aged 18 to 79 years enrolled in Renown Health, a large health system in Northern Nevada. Genotype was known for 38\u202f003 patients enrolled in Healthy Nevada Project (HNP), a population genomics study.<\/jats:p><\/jats:sec>Exposure<\/jats:title>An EHR indicating that a patient is positive for criteria according to the Seven-Question Family History Questionnaire (hereafter, FHS7 positive) assessing familial risk for hereditary breast and ovarian cancer (HBOC).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcomes were the presence of P\/LP variants in the ATM<\/jats:italic>, BRCA1<\/jats:italic>, BRCA2<\/jats:italic>, CHEK2<\/jats:italic>, or PALB2<\/jats:italic> genes (cross-sectional analysis) or a diagnosis of cancer (cohort analysis). Age-adjusted cancer incidence rates per 100\u202f000 patients per year were calculated using the 2020 US population as the standard. Hazard ratios (HRs) for cancer attributable to FHS7-positive status were estimated using cause-specific hazard models.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 835\u202f727 patients, 423\u202f393 (50.7%) were female and 29\u202f913 (3.6%) were FHS7 positive. Among those who were FHS7 positive, 24\u202f535 (82.0%) had no evidence of prior genetic testing for HBOC in their EHR. Being FHS7 positive was associated with increased prevalence of P\/LP variants in BRCA1<\/jats:italic>\/BRCA2<\/jats:italic> (odds ratio [OR], 3.34; 95% CI, 2.48-4.47), CHEK2<\/jats:italic> (OR, 1.62; 95% CI, 1.05-2.43), and PALB2<\/jats:italic> (OR, 2.84; 95% CI, 1.23-6.16) among HNP female individuals, and in BRCA1<\/jats:italic>\/BRCA2<\/jats:italic> (OR, 3.35; 95% CI, 1.93-5.56) among HNP male individuals. Being FHS7 positive was also associated with significantly increased risk of cancer among 131\u202f622 non-HNP female individuals (HR, 1.44; 95% CI, 1.22-1.70) but not among 114\u202f982 non-HNP male individuals (HR, 1.11; 95% CI, 0.87-1.42). Among 1527 HNP survey respondents, 352 of 383 EHR-FHS7 positive patients (91.9%) were survey-FHS7 positive, but only 352 of 883 survey-FHS7 positive patients (39.9%) were EHR-FHS7 positive. Of the 29\u202f913 FHS7-positive patients, 19\u202f764 (66.1%) were identified only after parsing free-text family history comments. Socioeconomic differences were also observed between EHR-FHS7-negative and EHR-FHS7-positive patients, suggesting disparities in recording family history.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study, EHR-derived FHS7 identified thousands of patients with familial risk for breast cancer, indicating a substantial gap in genetic testing. However, limitations in EHR family history data suggested that other identification methods, such as direct-to-patient questionnaires, are required to fully address this gap.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.35901","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:41:00Z","timestamp":1727300460000},"page":"e2435901","source":"Crossref","is-referenced-by-count":11,"title":["Screening Familial Risk for Hereditary Breast and Ovarian Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Daniel","family":"Kiser","sequence":"first","affiliation":[{"name":"University of Nevada Reno School of Medicine, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gai","family":"Elhanan","sequence":"additional","affiliation":[{"name":"University of Nevada Reno School of Medicine, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bolze","sequence":"additional","affiliation":[{"name":"Helix, Inc, San Mateo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Neveux","sequence":"additional","affiliation":[{"name":"University of Nevada Reno School of Medicine, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Schlauch","sequence":"additional","affiliation":[{"name":"University of Nevada Reno School of Medicine, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Metcalf","sequence":"additional","affiliation":[{"name":"University of Nevada Reno School of Medicine, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T.","family":"Cirulli","sequence":"additional","affiliation":[{"name":"Helix, Inc, San Mateo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"McCarthy","sequence":"additional","affiliation":[{"name":"University of Nevada Reno School of Medicine, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"University of Nevada Reno School of Medicine, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savanna","family":"Grime","sequence":"additional","affiliation":[{"name":"Renown Health, Reno, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie M. Schnell","family":"Blitstein","sequence":"additional","affiliation":[{"name":"Renown Health, Reno, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Plauth","sequence":"additional","affiliation":[{"name":"Renown Health, Reno, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Grzymski","sequence":"additional","affiliation":[{"name":"University of Nevada Reno School of Medicine, Reno"},{"name":"Renown Health, Reno, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"issue":"8","key":"zoi241064r1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41591-020-0982-5","article-title":"Population genetic screening efficiently identifies carriers of autosomal dominant diseases.","volume":"26","author":"Grzymski","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"zoi241064r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult biobank participants.","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi241064r3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13073-019-0691-1","article-title":"Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.","volume":"12","author":"Abul-Husn","year":"2019","journal-title":"Genome Med"},{"key":"zoi241064r4","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.866169","article-title":"Incomplete penetrance of population-based genetic screening results in electronic health record.","volume":"13","author":"Elhanan","year":"2022","journal-title":"Front Genet"},{"issue":"8","key":"zoi241064r5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/jmedgenet-2017-105195","article-title":"Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.","volume":"55","author":"Manchanda","year":"2018","journal-title":"J Med Genet"},{"issue":"8","key":"zoi241064r6","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/tbj.13969","article-title":"Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.","volume":"26","author":"Wood","year":"2020","journal-title":"Breast J"},{"issue":"5","key":"zoi241064r7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer.","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi241064r8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes: association analysis in more than 113,000 women.","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med"},{"key":"zoi241064r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2024.101826","article-title":"Combining rare and common genetic variants improves population risk stratification for breast cancer.","author":"Bolze","year":"2024","journal-title":"Genet Med Open"},{"issue":"1","key":"zoi241064r10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41391-017-0018-5","article-title":"Germline BRCA mutation in male carriers\u2014ripe for precision oncology?","volume":"21","author":"Le\u00e3o","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"14","key":"zoi241064r11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants.","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi241064r12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families.","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi241064r13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/s12885-017-3631-8","article-title":"CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.","volume":"17","author":"Hallamies","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"zoi241064r14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers.","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"zoi241064r15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-018-4098-y","article-title":"Male BRCA mutation carriers: clinical characteristics and cancer spectrum.","volume":"18","author":"Ibrahim","year":"2018","journal-title":"BMC Cancer"},{"key":"zoi241064r16","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9003572","article-title":"Male breast cancer: an updated review of patient characteristics, genetics, and outcome.","volume":"2024","author":"Khare","year":"2024","journal-title":"Int J Breast Cancer"},{"issue":"7","key":"zoi241064r21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement.","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"zoi241064r22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/1471-2407-9-283","article-title":"Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care.","volume":"9","author":"Ashton-Prolla","year":"2009","journal-title":"BMC Cancer"},{"issue":"4","key":"zoi241064r23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"7905","key":"zoi241064r26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41586-022-04558-8","article-title":"A joint NCBI and EMBL-EBI transcript set for clinical genomics and research.","volume":"604","author":"Morales","year":"2022","journal-title":"Nature"},{"issue":"4","key":"zoi241064r27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","article-title":"NCCN Guidelines Insights: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.","volume":"18","author":"Daly","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"zoi241064r29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks.","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"zoi241064r30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals.","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"7","key":"zoi241064r33","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jama.2019.8430","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"zoi241064r34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/1940-6207.CAPR-20-0002","article-title":"Population-based genetic testing for precision prevention.","volume":"13","author":"Evans","year":"2020","journal-title":"Cancer Prev Res (Phila)"},{"issue":"7","key":"zoi241064r35","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/cancers13071486","article-title":"Psychosocial interventions for women with a BRCA1 or BRCA2 mutation: a scoping review.","volume":"13","author":"Boghosian","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"zoi241064r36","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus guidelines on genetic\u2019 testing for hereditary breast cancer from the American Society of Breast Surgeons.","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"zoi241064r37","doi-asserted-by":"publisher","DOI":"10.2196\/23523","article-title":"Barriers and facilitators to genetic service delivery models: scoping review.","volume":"10","author":"Raspa","year":"2021","journal-title":"Interact J Med Res"},{"issue":"4","key":"zoi241064r38","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.clbc.2019.02.009","article-title":"Implementing a population-based breast cancer risk assessment program.","volume":"19","author":"Silver","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"zoi241064r39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/tbj.13722","article-title":"Importance of family history and indications for genetic testing.","volume":"26","author":"Wood","year":"2020","journal-title":"Breast J"},{"key":"zoi241064r40","first-page":"173","article-title":"Determining onset for familial breast and colorectal cancer from family history comments in the electronic health record.","volume":"2019","author":"Mowery","year":"2019","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"issue":"8","key":"zoi241064r41","doi-asserted-by":"publisher","DOI":"10.2196\/37842","article-title":"Identifying patients who meet criteria for genetic testing of hereditary cancers based on structured and unstructured family health history data in the electronic health record: natural language processing approach.","volume":"10","author":"Shi","year":"2022","journal-title":"JMIR Med Inform"},{"issue":"7","key":"zoi241064r42","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.cgh.2019.12.007","article-title":"Improving patient-provider relationships to improve health care.","volume":"18","author":"Drossman","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1079","key":"zoi241064r43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/postgradmedj-2014-133195","article-title":"Implementation of health risk assessments with family health history: barriers and benefits.","volume":"91","author":"Wu","year":"2015","journal-title":"Postgrad Med J"},{"issue":"2","key":"zoi241064r44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/01.GIM.0000055197.23822.5E","article-title":"The genetic family history as a risk assessment tool in internal medicine.","volume":"5","author":"Frezzo","year":"2003","journal-title":"Genet Med"},{"issue":"2","key":"zoi241064r45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000160667","article-title":"Family history questionnaires designed for clinical use: a systematic review.","volume":"12","author":"Reid","year":"2009","journal-title":"Public Health Genomics"},{"issue":"2","key":"zoi241064r46","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.2002.20.2.528","article-title":"Identification and referral of families at high risk for cancer susceptibility.","volume":"20","author":"Sweet","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi241064r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34574","article-title":"Association of disparities in family history and family cancer history in the electronic health record with sex, race, Hispanic or Latino ethnicity, and language preference in 2 large US health care systems.","volume":"5","author":"Chavez-Yenter","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi241064r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pecinn.2022.100087","article-title":"Barriers to family history collection among Spanish-speaking primary care patients: a BRIDGE qualitative study.","volume":"1","author":"Liebermann","year":"2022","journal-title":"PEC Innov"},{"key":"zoi241064r49","doi-asserted-by":"publisher","DOI":"10.5888\/pcd17.200257","article-title":"Prevalence and correlates of family cancer history knowledge and communication among US adults.","volume":"17","author":"Krakow","year":"2020","journal-title":"Prev Chronic Dis"},{"key":"zoi241064r51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.00120","article-title":"Standards-based clinical decision support platform to manage patients who meet guideline-based criteria for genetic evaluation of familial cancer.","volume":"4","author":"Del Fiol","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"5-6","key":"zoi241064r52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000525447","article-title":"An electronic health record tool increases genetic counseling referral of individuals at hereditary cancer risk: an intervention study.","volume":"25","author":"Wurtmann","year":"2022","journal-title":"Public Health Genomics"},{"issue":"5","key":"zoi241064r53","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/jamia\/ocac028","article-title":"GARDE: a standards-based clinical decision support platform for identifying population health management cohorts.","volume":"29","author":"Bradshaw","year":"2022","journal-title":"J Am Med Inform Assoc"},{"issue":"3","key":"zoi241064r54","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3122\/jabfm.2015.03.140149","article-title":"Prompting primary care providers about increased patient risk as a result of family history: does it work?","volume":"28","author":"Zazove","year":"2015","journal-title":"J Am Board Fam Med"},{"key":"zoi241064r55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13012-015-0209-1","article-title":"A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project.","volume":"10","author":"Powell","year":"2015","journal-title":"Implement Sci"},{"issue":"6","key":"zoi241064r56","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/ajg.2009.135","article-title":"Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy.","volume":"104","author":"Kastrinos","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"zoi241064r57","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jamia\/ocac050","article-title":"Informative presence bias in analyses of electronic health records-derived data: a cautionary note.","volume":"29","author":"Harton","year":"2022","journal-title":"J Am Med Inform Assoc"},{"key":"zoi241064r17","unstructured":"Renown Health. What Is the Healthy Nevada Project? Accessed April 15, 2024. https:\/\/www.renown.org\/blog\/what-is-the-healthy-nevada-project"},{"key":"zoi241064r18","unstructured":"Healthy Nevada Project. Accessed April 15, 2024. https:\/\/healthynv.org\/"},{"key":"zoi241064r19","unstructured":"National Cancer Institute. BRCA gene changes: cancer risk and genetic testing. Accessed March 21, 2024. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet"},{"key":"zoi241064r20","unstructured":"Nevada State Legislature. Senate Bill 251. 81st Legislature. Revises provisions relating to genetic counseling and testing (BDR 40-478). March 15, 2021. Accessed August 21, 2024. https:\/\/www.leg.state.nv.us\/App\/NELIS\/REL\/81st2021\/Bill\/7773\/Overview"},{"key":"zoi241064r24","unstructured":"Nevada Department of Health and Human Services. Death Certificate Data. Accessed March 2023. https:\/\/dhhs.nv.gov\/"},{"key":"zoi241064r25","unstructured":"US Census Bureau. American Community Survey (ACS) 5-Year Data. 2020. Accessed March 20, 2024. https:\/\/api.census.gov\/data\/2020\/acs\/acs5"},{"key":"zoi241064r28","unstructured":"Centers for Disease Control and Prevention. United States Cancer Statistics (USCS): demographics. Accessed April 2, 2024. https:\/\/gis.cdc.gov\/Cancer\/USCS\/#\/Demographics\/"},{"key":"zoi241064r31","doi-asserted-by":"crossref","unstructured":"Murray? MF, Evans? JP, Angrist? M, . A proposed approach for implementing genomics-based screening programs for healthy adults. National Academy of Medicine. December 3, 2018. Accessed August 21, 2024. https:\/\/nam.edu\/a-proposed-approach-for-implementing-genomics-based-screening-programs-for-healthy-adults\/","DOI":"10.31478\/201812a"},{"key":"zoi241064r32","unstructured":"MassMutual. Genomics plc and MassMutual\u2019s program enables more policyowners to understand health risks through innovative genetic testing. April 9, 2024. Accessed August 21, 2024. https:\/\/www.massmutual.com\/about-us\/news-and-press-releases\/press-releases\/2024\/04\/genomics-plc-and-massmutuals-program-enables-more-policyowners-to-understand-health"},{"key":"zoi241064r50","unstructured":"Petrucelli? N, Daly? MB, Pal? T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. September 4, 1998. Accessed August 21, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824047\/kiser_2024_oi_241064_1726669140.0546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:41:09Z","timestamp":1727300469000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.35901","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]}}}